We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+30.23%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$365M
Cap. Flow
+$51.2M
Cap. Flow %
2.74%
Top 10 Hldgs %
59.4%
Holding
57
New
5
Increased
14
Reduced
4
Closed
8

Top Buys

1
ETNB
89bio
ETNB
+$18.4M
2
GPCR icon
Structure Therapeutics
GPCR
+$18.2M
3
APLS
Apellis Pharmaceuticals
APLS
+$13.8M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$12.8M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.1M

Top Sells

1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$36.6M
2
ELVN icon
Enliven Therapeutics
ELVN
+$14.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.71M
4
REPL icon
Replimune Group
REPL
+$6.62M
5
PRTA icon
Prothena Corp
PRTA
+$6.17M

Sector Composition

1 Healthcare 99.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.11B
$19.7M 1.05%
2,142,855
– –
ANAB icon
27
AnaptysBio
ANAB
$1.6B
$19.3M 1.03%
899,700
– –
SVRA icon
28
Savara
SVRA
$1.13B
$18.8M 1.01%
4,000,000
– –
SLNO
29
DELISTED
Soleno Therapeutics
SLNO
$18.7M 1%
464,937
– –
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$16.7M 0.89%
393,000
– –
DCPH
31
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.5M 0.88%
1,021,800
+651,800
+176% +$8.31M
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$12.6B
$16.1M 0.86%
+69,406
New +$12.1M
DYN icon
33
Dyne Therapeutics
DYN
$3.76B
$15.8M 0.84%
+1,184,840
New +$11.6M
SLN
34
Silence Therapeutics
SLN
$516M
$15.3M 0.82%
881,173
– –
TYRA icon
35
Tyra Biosciences
TYRA
$1.88B
$14.2M 0.76%
1,026,420
-1,593
-0.2% -$20.6K
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$8.88B
$14.1M 0.76%
397,483
-1,192,448
-75% -$36.6M
GPCR icon
37
Structure Therapeutics
GPCR
$3.27B
$12.9M 0.69%
+317,190
New +$18.2M
ARVN icon
38
Arvinas
ARVN
$518M
$11.7M 0.63%
285,331
– –
COGT icon
39
Cogent Biosciences
COGT
$6.48B
$11.7M 0.63%
1,995,267
+493,884
+33% +$3.78M
AGIO icon
40
Agios Pharmaceuticals
AGIO
$2.3B
$11.7M 0.62%
523,166
+231,164
+79% +$5.18M
APGE icon
41
Apogee Therapeutics
APGE
$10.1B
$11.2M 0.6%
400,000
– –
TRVI icon
42
Trevi Therapeutics
TRVI
$2.46B
$9.89M 0.53%
7,381,090
+500,000
+7% +$757K
THRX
43
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$8.58M 0.46%
2,118,051
-130,143
-6% -$397K
NTLA icon
44
Intellia Therapeutics
NTLA
$1.66B
$6.21M 0.33%
203,684
– –
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.7M 0.25%
+80,000
New +$4.5M
BLUE
46
DELISTED
bluebird bio
BLUE
$2.36M 0.13%
85,495
– –
GRTS
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.1M 0.11%
1,030,878
-400,000
-28% -$730K
NAMSW icon
48
NewAmsterdam Pharma Warrant
NAMSW
$94.6M
$1.57M 0.08%
500,333
– –
ACRS icon
49
Aclaris Therapeutics
ACRS
$749M
$278K 0.01%
264,377
– –
ADCT icon
50
ADC Therapeutics
ADCT
$172M
– –
-1,647,030
Closed -$1.48M
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2023 Portfolio in Review

As of Q4 2023, Frazier Life Sciences Management held 57 positions worth $1.87B, up 24% from $1.51B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Frazier Life Sciences Management's Q4 2023 filing shows 5 new, 14 increased, 4 reduced and 8 closed positions. Its largest new stake was 89bio: 2,000,000 shares worth $22.3M. The largest sale was Crinetics Pharmaceuticals, an estimated $36.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q4 2023 buy was 89bio: 2,000,000 shares worth $22.3M.
  • Frazier Life Sciences Management added most to Apellis Pharmaceuticals in Q4 2023, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q4 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $36.6M.
  • Frazier Life Sciences Management fully exited Enliven Therapeutics in Q4 2023, selling an estimated $14.3M.
  • Frazier Life Sciences Management's ten largest holdings make up 59% of its $1.87B portfolio in Q4 2023.
  • Frazier Life Sciences Management opened 5 new positions and closed 8 in Q4 2023.
  • Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.87B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2023, filed 14 Feb 2024.